You are not currently logged in.
Access JSTOR through your library or other institution:
Atovaquone and Proguanil versus Amodiaquine for the Treatment of Plasmodium falciparum Malaria in African Infants and Young Children
Steffen Borrmann, Jean-François Faucher, Thierry Bagaphou, Michel A. Missinou, Ronald K. Binder, Sophia Pabisch, Philipp Rezbach, Pierre-Blaise Matsiegui, Bertrand Lell, Gerri Miller and Peter G. Kremsner
Clinical Infectious Diseases
Vol. 37, No. 11 (Dec. 1, 2003), pp. 1441-1447
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4483718
Page Count: 7
You can always find the topics here!Topics: Parasites, Malaria, Falciparum malaria, Children, Infants, Child development, Medical treatment failures, Dosage, Drug evaluation, Child health services
Were these topics helpful?See something inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Malaria-related morbidity and mortality are greatest among young children in areas with high malaria transmission intensity. An open-label, randomized study was done to evaluate the efficacy and safety of the combination of atovaquone and proguanil formulated as pediatric-strength tablets (20 and 8 mg/kg of body weight, respectively, administered once daily for 3 days), compared with amodiaquine (10 mg/kg of body weight, once daily for 3 days), among children weighing ≥5 and <11 kg in Gabon. Two hundred patients aged 3-43 months were recruited. Use of atovaquone/proguanil resulted in a cure rate on day 28 of 95% (87 of 92 children), compared with 53% (41 of 78 children) for amodiaquine (difference, 42%; 95% CI, 30%-54%; P < .001). The incidence of adverse events was similar in both groups, and no serious adverse events were attributed to the use of atovaquone/proguanil. Atovaquone/proguanil was found to be highly effective and safe for the treatment of Plasmodium falciparum malaria in infants and young children weighing 5-10 kg in Africa.
Clinical Infectious Diseases © 2003 Oxford University Press